Our Vision
Our vision is to be a leader in identifying, developing and commercializing novel drugs that address unmet needs of people with rare cancer conditions.
Learn more about Ascelia Pharma:
TOP STORIES
Ascelia Pharma provides Orviglance® update following FDA Type A meeting
2026-10-11 14:25:00
Ascelia Pharma AB (publ) today announces that it has received the official minutes from its Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the Complete Response […]
TOP STORIES
Ascelia Pharma Announces FDA Has Scheduled Type A Meeting for Orviglance NDA on September 9, 2026
2026-08-17
Ascelia Pharma AB (publ) (STO: ACE), a biotech company focused on improving the lives of people living with rare cancer conditions, today announced that the U.S. Food and Drug Administration [… …
TOP STORIES
Ascelia Pharma Expands Orviglance IP Portfolio with New Patent Filing
2026-06-30
Ascelia Pharma AB (publ) (ticker: ACE), a biotech company focused on improving the life of people living with rare cancer conditions, today announced the filing of a new patent application […]
Latest News
Presentations & Articles
INVESTOR
Shortcut to our latest Financial Reports
Key downloads
Half-Year Report 2026: Focus on the Path Forward for OrviglanceQuarterly Report Q1 2026: Orviglance® Approaching Transformative MilestonesAnnual Report 2025: Orviglance NDA submitted to the FDA, PDUFA-date set for July 2026Full Year and Q4 Report 2025: FDA Accepts Orviglance NDA for ReviewQuarterly Report Q3 2025: Orviglance NDA Submitted to the FDA